SG Americas Securities LLC Acquires 7,404 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

SG Americas Securities LLC raised its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 60.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 19,646 shares of the biopharmaceutical company’s stock after buying an additional 7,404 shares during the period. SG Americas Securities LLC’s holdings in Ocular Therapeutix were worth $88,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in OCUL. Nuveen Asset Management LLC grew its stake in shares of Ocular Therapeutix by 376.4% during the 2nd quarter. Nuveen Asset Management LLC now owns 919,602 shares of the biopharmaceutical company’s stock worth $4,745,000 after acquiring an additional 726,569 shares in the last quarter. Federated Hermes Inc. bought a new position in shares of Ocular Therapeutix in the first quarter valued at $3,080,000. Marshall Wace LLP acquired a new position in Ocular Therapeutix during the third quarter worth $2,207,000. Renaissance Technologies LLC increased its holdings in Ocular Therapeutix by 537.7% during the first quarter. Renaissance Technologies LLC now owns 510,805 shares of the biopharmaceutical company’s stock worth $2,528,000 after buying an additional 430,705 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in Ocular Therapeutix by 7.0% during the second quarter. BlackRock Inc. now owns 5,262,920 shares of the biopharmaceutical company’s stock worth $27,157,000 after buying an additional 344,611 shares during the last quarter. 59.21% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Rabia Gurses Ozden sold 7,764 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total transaction of $38,431.80. Following the completion of the transaction, the insider now owns 92,767 shares of the company’s stock, valued at $459,196.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Ocular Therapeutix news, General Counsel Philip C. Strassburger sold 6,831 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total transaction of $33,813.45. Following the completion of the transaction, the general counsel now owns 109,218 shares of the company’s stock, valued at $540,629.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rabia Gurses Ozden sold 7,764 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total value of $38,431.80. Following the transaction, the insider now directly owns 92,767 shares of the company’s stock, valued at approximately $459,196.65. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,366 shares of company stock valued at $194,862. 5.50% of the stock is currently owned by corporate insiders.

Ocular Therapeutix Trading Down 10.9 %

OCUL opened at $5.22 on Friday. Ocular Therapeutix, Inc. has a twelve month low of $2.00 and a twelve month high of $11.31. The company has a 50-day simple moving average of $8.75 and a 200 day simple moving average of $5.31. The company has a quick ratio of 6.59, a current ratio of 6.66 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $775.85 million, a price-to-earnings ratio of -4.18 and a beta of 1.30.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). Ocular Therapeutix had a negative net margin of 138.15% and a negative return on equity of 321.12%. The business had revenue of $14.80 million during the quarter, compared to analysts’ expectations of $15.31 million. Analysts predict that Ocular Therapeutix, Inc. will post -0.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Piper Sandler boosted their target price on shares of Ocular Therapeutix from $10.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, February 26th. JMP Securities reaffirmed a “market outperform” rating and set a $24.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, April 16th. Bank of America initiated coverage on shares of Ocular Therapeutix in a research report on Friday, February 9th. They set a “buy” rating and a $15.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Ocular Therapeutix in a research report on Friday. Finally, StockNews.com cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and an average target price of $17.60.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.